Sign Up Today and Learn More About Dren Bio Stock
Invest in or calculate the value of your shares in Dren Bio or other pre-IPO companies through EquityZen's platform.

Dren Bio Stock (DRBI)
Dren Bio focuses on protein engineering technologies for depletion of cells, protein aggregates, and other disease-causing agents.
About Dren Bio Stock
Founded
2019
Headquarters
Foster City, CA, US
Industries
Science and Engineering, Health Care, Biotechnology
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Dren Bio Press Mentions
Stay in the know about the latest news on Dren Bio
Multispecific binding proteins that bind to dectin-1 and cd20 and methods of …
patents • Apr 02, 2025
Multispecific binding proteins that bind dectin-1 and trop-2 and methods of use …
patents • Apr 02, 2025
Antibodies against dectin-1 and methods of using them
patents • Apr 02, 2025
Sanofi Strengthens Immunology Portfolio with $1.9 Billion Acquisition of Dren Bio’s Unit
cordmagazine • Mar 26, 2025
Serbian scientists sell autoimmune disease and cancer treatment for USD 1.9 billion – Sanofi buys biopharma company Dren Bio
ekapija • Mar 26, 2025
Dren Bio Management
Leadership team at Dren Bio
CEO and Co-Fonder
Nenad Tomasevic
Co-Founder, CFO
John Wesley

Join now and verify your accreditation status to gain access to:
- Dren Bio Current Valuation
- Dren Bio Stock Price
- Dren Bio Management
- Available deals in Dren Bio and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Dren Bio Cap Table and Funding History by Share Class and Liquidity Preferences
- Dren Bio Revenue and Financials
- Dren Bio Highlights
- Dren Bio Business Model
- Dren Bio Risk Factors
- Dren Bio Research Report from SACRA Research
Trading Dren Bio Stock
How to invest in Dren Bio stock?
Accredited investors can buy pre-IPO stock in companies like Dren Bio through EquityZen funds. These investments are made available by existing Dren Bio shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Dren Bio stock?
Shareholders can sell their Dren Bio stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."